Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease modifying antirheumatic drugs: longterm safety issues.

H A Capell1

  • 1Center Rheumatic Disease Ward 14-15, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, Scotland G40SF.

The Journal of Rheumatology. Supplement
|June 21, 2001
PubMed
Summary

Evaluating long-term safety of disease-modifying antirheumatic drugs (DMARDs) is crucial for rheumatoid arthritis management. This review examines adverse events from long-term DMARD studies to guide benefit-risk assessments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.

Arthritis and rheumatism·2008
Same author

A pilot study of a Mediterranean-type diet intervention in female patients with rheumatoid arthritis living in areas of social deprivation in Glasgow.

Annals of the rheumatic diseases·2007
Same author

Audit of literacy of medical patients in north Glasgow.

Scottish medical journal·2007
Same author

Corticosteroids in the management of early and established rheumatoid disease.

Rheumatology (Oxford, England)·2006
Same author

Neuropathies in the rheumatoid patient: a case of the heavy hand.

Scottish medical journal·2005
Same author

Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial.

Annals of the rheumatic diseases·2004

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Medicine

Background:

  • Aggressive rheumatoid arthritis management involves early introduction of disease-modifying antirheumatic drugs (DMARDs).
  • Patients may require DMARD therapy for decades, necessitating thorough long-term safety evaluations.
  • Assessing long-term safety is challenging due to limited extended trials and polypharmacy (DMARDs with NSAIDs and corticosteroids).

Purpose of the Study:

  • To review long-term studies of disease-modifying antirheumatic drugs (DMARDs).
  • To provide insight into the adverse events associated with currently available DMARDs.
  • To inform benefit-risk assessments for long-term rheumatoid arthritis treatment.

Main Methods:

  • Review of existing long-term studies involving disease-modifying antirheumatic drugs (DMARDs).

Related Experiment Videos

  • Analysis of reported adverse events in patients undergoing extended DMARD therapy.
  • Consideration of confounding factors such as concurrent use of nonsteroidal anti-inflammatory drugs and corticosteroids.

    • Main Results:

    • Identification of specific adverse events associated with various long-term DMARD treatments.
    • Insights into the safety profiles of commonly prescribed DMARDs over extended periods.
    • Data supporting the complexity of attributing adverse events in patients on combination therapy.

    Conclusions:

    • Long-term safety data for disease-modifying antirheumatic drugs (DMARDs) is essential for rheumatoid arthritis care.
    • Understanding DMARD adverse events aids in optimizing patient management and treatment strategies.
    • Further research into long-term DMARD safety, especially in combination therapies, is warranted.